Cost-benefit analysis of tuberculosis prevention and control program from 2006 to 2015 in Taian

doi:10.3969/j.issn.1000-6621.2018.04.016

Abstract

Abstract:

This study retrospectively analyzed the cost-benefit of the tuberculosis (TB) prevention and control plan in Taian city during the “11th Five-year” and the “12th Five-year” period by referring the methods on calculation of social cost, social effect, social benefit and cost-effectiveness ratio, which were used in the “Evaluation Protocol of National TB Control Program (2001-2010)”. The aim of this study was to provide reference for the implementation of the 13th Five-year plan for TB control and prevention in Taian City. This study shows that, during the “11th Five-year” period, the total funds used for TB prevention and treatment was RMB 10.7779 million yuan in Taian City, a total of 14936 patients with active pulmonary tuberculosis were notified for receiving free treatment, and 64426 persons were avoided from TB infections, 6443 persons were prevented to develop active TB. It was estimated that RMB 4.3893 million yuan medical expenses and around RMB 1.5 billion yuan overall social economic value were saved; it meant that RMB 1 yuan investment from the government can generate RMB 142.89 yuan social economic benefits. During the “12th Five-year” period, the total funds used for TB prevention and treatment was RMB 13.507 million yuan in Taian City, a total of 12146 patients with active pulmonary TB were notified for receiving free treatment, and 42623 persons were avoided from TB infections, 4263 persons were prevented to develop active TB. It was estimated that RMB 3.6 million yuan medical expenses and around RMB 2.3 billion yuan overall social economic value were saved; it meant that RMB 1 yuan investment from the government can generate RMB 169.65 yuan social economic benefits. This research suggests the cost-effectiveness of the TB prevention and control programme was obvious in Taian city by implementations of the 11th Five-year and the 12th Five-year TB prevention and control program, and the social economic benefits in implementation of the 12th Five-year plan period were higher than that in the implementation of the 11th Five-year plan period.

Key words: Tuberculosis, Universal precautions, Health expenditures, Cost-benefit analysis, Small-area analysis

Jian-zhi LI,Jun LI,Ting REN,Ning LI. Cost-benefit analysis of tuberculosis prevention and control program from 2006 to 2015 in Taian[J]. Chinese Journal of Antituberculosis, 2018, 40(4): 429-433. doi: 10.3969/j.issn.1000-6621.2018.04.016

Figures/Tables 4

References 14

[1]	World Health Organization. Global tuberculosis report 2016. Geneva:World Health Organization, 2016.
[2]	阮云洲, 何广学, 成诗明 , 等. 结核病防治社会效益评估方法探讨及应用. 中国防痨杂志, 2012,34(9):604-610.
[3]	中华人民共和国国家统计局社会科技统计司. 中国社会统计年鉴.北京: 中国统计出版社, 2006.
[4]	中华人民共和国卫生部, 中华人民共和国发展改革委, 中华人民共和国财政部.关于开展《全国结核病防治规划(2001—2010年)》终期评估的通知[卫办疾控发〔2010〕147号][EB/OL].( 2010- 09- 02)[2018-01-03]. .
[5]	龚幼龙, 万利亚, 吴桂英 , 等. 结核病控制经济与管理学评价.上海: 第二军医大学出版社, 2003.
[6]	代水琼, 普洪学, 赵子辉 , 等. 云南省峨山县“十二五”规划期间结核病防治成本效益分析. 中国防痨杂志, 2017,39(3):318-321. doi: 10.3969/j.issn.1000-6621.2017.03.024 URL
[7]	王艳飞, 曾令诚, 柳巍 , 等. 西安市结核病防治“十二五”规划成本-效果与效益评估. 现代预防医学, 2016,43(20):3742-3744.
[8]	靳晓伟, 魏晓慧, 段海霞 , 等. 新密市”十二五”规划实施的成本效益分析. 结核病与肺部健康杂志, 2016,5(4):288-291.
[9]	李月华, 郝艳艳, 姚丽丹 , 等. 2011—2015年新疆维吾尔自治区实施结核病防治规划的成本效益分析. 中国防痨杂志, 2017,39(2):174-178. doi: 10.3969/j.issn.1000-6621.2017.02.014 URL
[10]	戴志澄, 肖东楼, 万利亚 . 中国防痨史.北京: 人民卫生出版社, 2013.
[11]	管红云, 杨应周, 谭卫国 , 等. 深圳市结核病防治规划(2001—2010年)》实施效能评价. 中国防痨杂志, 2013,35(9):729-737.
[12]	肖东楼 . 全国结核病防治规划(2001—2010年)终期评估报告.北京: 军事医学科学出版社, 2011.
[13]	李建之, 孟凡亮 . 山东省泰安市“十一五”和“十二五”期间结核病防治规划实施效果对比研究. 中国防痨杂志, 2017,39(6):630-637. doi: 10.3969/j.issn.1000-6621.2017.06.017 URL
[14]	中华人民共和国卫生和计划生育委员会办公厅.关于印发结核病患者健康管理服务规范的通知 [国卫办基层函〔2015〕880号][EB/OL].( 2015- 10- 27)[2018-01-03]. .

年份	财政经费(万元)					项目经费(万元)				总经费(社会总成本, 万元)	财政经费定基比	总经费定基比
年份	中央经费	省级经费	市级经费	县级经费	小计	全球基金	省级项目	其他项目	小计	总经费(社会总成本, 万元)	财政经费定基比	总经费定基比
2006	50.85	18.06	16.50	27.20	112.61	15.26	0.00	4.05	19.31	131.92	-	-
2007	81.88	13.16	16.50	39.20	150.74	24.01	0.00	4.95	28.96	179.70	1.34	1.36
2008	90.74	34.68	16.50	44.20	186.12	22.22	0.00	0.00	22.22	208.34	1.65	1.58
2009	92.91	16.71	25.00	108.20	242.82	40.89	0.00	0.00	40.89	283.71	2.16	2.15
2010	91.43	2.00	25.00	117.20	235.63	38.49	0.00	0.00	38.49	274.12	2.09	2.08
合计	407.81	84.61	99.50	336.00	927.92	140.87	0.00	9.00	149.87	1077.79	-	-
2011	94.84	0.00	31.70	87.66	214.20	31.38	3.17	0.00	34.55	248.75	-	-
2012	75.99	0.00	36.70	78.86	191.55	28.76	2.26	0.00	31.02	222.57	0.89	0.89
2013	101.54	0.00	71.70	101.86	275.10	0.00	2.91	0.00	2.91	278.01	1.28	1.12
2014	113.64	0.00	65.00	101.86	280.50	0.00	13.91	0.00	13.91	294.41	1.31	1.18
2015	131.76	0.00	65.00	101.86	298.62	0.00	8.38	0.00	8.38	307.00	1.39	1.23
合计	517.77	0.00	270.10	472.10	1259.97	60.14	30.63	0.00	90.77	1350.74	-	-
总计	925.58	84.61	369.60	808.10	2187.89	201.01	30.63	9.00	240.64	2428.53	-	-

年份	涂阳患者治疗成功例数	涂阴患者治疗成功例数	规划贡献因子	避免感染例数	避免新发病例数
2006	2164	359	0.6	13630	1363
2007	1797	797	0.6	12217	1222
2008	1899	1098	0.6	13370	1337
2009	1752	1081	0.6	12458	1246
2010	1796	1097	0.6	12751	1275
合计	9408	4432	-	64426	6443
2011	1319	938	0.6	9602	960
2012	1118	1171	0.6	8816	882
2013	1075	1361	0.6	8900	890
2014	912	1502	0.6	8176	818
2015	779	1364	0.6	7129	713
合计	5203	6336	-	42623	4263
总计	14611	10768	-	107049	10706

年份	避免新发患者例数	次均门诊医疗费用(元)	减少的医疗费用(元)
2006	1363	136.25	928543.75
2007	1222	136.25	832487.50
2008	1337	136.25	910831.25
2009	1246	136.25	848837.50
2010	1275	136.25	868593.75
合计	6443	-	4389293.75
2011	960	141.00	676800.00
2012	882	158.20	697662.00
2013	890	175.40	780530.00
2014	818	185.70	759513.00
2015	713	193.40	689471.00
合计	4263	-	3603976.00
总计	10706	-	7993269.75

年份	活动性患者治疗成功例数	治疗1例患者挽回的DALY	挽回的总DALY	活动性患者劳动力人口比例^[5]	人均国内生产总值(元)	挽回的社会总价值(元)
2006	1514	9.5	14383.0	0.7	18800	189280280.0
2007	1557	9.5	14791.5	0.7	22600	234001530.0
2008	1798	9.5	17081.0	0.7	28100	335983270.0
2009	1700	9.5	16150.0	0.7	31400	354977000.0
2010	1736	9.5	16492.0	0.7	36500	421370600.0
合计	8305	-	78897.5	-	-	1535612680.0
2011	1354	9.5	12863.0	0.7	41850	376821585.0
2012	1373	9.5	13043.5	0.7	46130	421187658.5
2013	1462	9.5	13889.0	0.7	50296	488992800.8
2014	1448	9.5	13756.0	0.7	53853	518561307.6
2015	1286	9.5	12217.0	0.7	56490	483096831.0
合计	6923	-	65768.5	-	-	2288660183.0
总计	15228	-	144666.0	-	-	3824272863.0

[1]	LIU Xiao-li, LEI Li-mei, GUO Zhou-li, HUANG Yin, XU Jing, ZHAO Xia, WANG Yan, FU Li. Study on the relationship of stigma and social support of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 1002-1008.
[2]	Academic Working Committee of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of fixed-dose combination formulations [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 885-893.
[3]	JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902.
[4]	ZHANG Can-you, XIA Hui, CHENG Jun. Testing and reporting requirements for Class Ⅱ biosafety cabinet in tuberculosis laboratory [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 903-909.
[5]	ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915.
[6]	LIU Er-yong, WANG Qian, ZHOU Lin, ZHANG Guo-qin, ZHANG Xiu-lei, MA Yong-cheng, YANG Shu-min, WANG Cui, MENG Qing-lin, CHEN Ming-ting, LIN Ming-gui, TU De-hua.. Analysis of diagnostic quality of pulmonary tuberculosis with negative etiology in some areas of China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 916-920.
[7]	MENG Qing-lin, LI Jin-lan, LIN Ding-wen, MA Yong-cheng, HOU Shuang-yi, LIU Nian-qiang, ZHOU Lin. Analysis of the awareness about knowledge on the updated TB diagnosis standard among the practitioners in TB control institutions [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 921-925.
[8]	WANG Qian, ZHOU Lin, LIU Er-yong, ZHAO Yan-lin, LI Tao, CHEN Ming-ting, YANG Li-jia, WANG Jia.. A survey on the diagnostic ability of tuberculosis in the county-level medical institutions in China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 926-930.
[9]	LI Ting, HE Jin-ge, SU Qian, LI Jing, LI Yun-kui, GAO Wen-feng, GAO Yuan, YANG Wen. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 931-936.
[10]	LI Yun-kui, HE Jin-ge, SU Qian, LI Ting, LI Jing, GAO Wen-feng, YANG Wen, MAO Guang-yu. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 937-941.
[11]	SU Qian, XIA Yong, LU Jia, WANG Dan-xia, HE Jin-ge. Analysis on the epidemiological characteristics of pulmonary tuberculosis among children aged 0-14 in Sichuan Province from 2009 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 942-947.
[12]	DENG Ya-li, ZHANG Tian-hua, LIU Wei-ping, ZHANG Hong-wei, MA Yu, LI Peng.. Temporal and spatial clustering analysis of pulmonary tuberculosis incidence in Shaanxi Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 948-955.
[13]	DONG Xiao, ZHAO Zhen, LIU Nian-qiang, WANG Sen-lu, CUI Yan. Analysis of the finding characteristics of pulmonary tuberculosis in the elderly population in Xinjiang Uygur Autonomous Region during 2009—2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 956-961.
[14]	MA Ting-long, HAN Yi, CHENG Xu, LIU Zhi-dong. Clinical observation on treatment effectiveness of transdermal ultrasound-mediated drug delivery combined with oral anti-tuberculosis drug in patients with chest wall tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 968-972.
[15]	NAN Hai, ZHANG Yun, YANG Xin-ting, DUAN Hong-fei. Meta-analysis on the diagnostic value of GeneXpert MTB/RIF for bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 973-980.